Latest News - Dry Eye

Monday, May 01, 2017 | Dry Eye, Partnerships, Parion Sciences, Shire

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Shire and Parion Sciences announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investi…

Read the full story

Thursday, April 06, 2017 | Acquisitions/Mergers, Dry Eye, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease

Imprimis Pharmaceuticals announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients…

Read the full story

Monday, March 20, 2017 | Dry Eye, Pharmaceutical, Novaliq

Novaliq Announces Licensing Agreement With AFT Pharmaceuticals for Distribution of NovaTears

Novaliq announced a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of Novaliq's lead product NovaTears in Australia and New Zealand. NovaTears is Novaliq&rsquo…

Read the full story

Friday, February 17, 2017 | Dry Eye, Earnings & Financials, Shire

Shire Provides Update on Early Xiidra Sales

As part of its fourth quarter and full-year earnings release on Thursday, Shire provided information about the early sales of its dry eye disease drug Xiidra (lifitegrast), which was launched in Augus…

Read the full story

Tuesday, January 17, 2017 | Dry Eye, Medical Studies

Faster Diagnosis Could Improve Quality of Life for People With Dry Eye Disease

Dry eye disease can be difficult to diagnose, and delays in diagnosis may lead to more severe symptoms and a greater impact on patients' daily lives, according to a European study. People with a d…

Read the full story

Wednesday, January 04, 2017 | Clinical Trials, Dry Eye, Sun Pharma

Sun Pharma Announces Positive Topline Results of Confirmatory Phase 3 Clinical Trial for Seciera for Treatment of Dry Eye

Sun Pharma announced successful phase 3 confirmatory clinical trial results for Seciera (cyclosporine A 0.09% ophthalmic solution) for the treatment of dry eye disease, according to a company news rel…

Read the full story

Thursday, November 10, 2016 | Clinical Trials, Dry Eye

RegeneRx Announces First Patients Enrolled in Phase 3 US Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259

RegeneRx Biopharmaceuticals announced that the first patients have been enrolled in a phase 3 clinical trial (ARISE-2 trial) with RGN-259 (Thymosin beta 4), its sterile, preservative-free eye drop for…

Read the full story

Tuesday, August 23, 2016 | Dry Eye, Medical Studies, TearScience

A Single LipiFlow Treatment Demonstrates Sustained Improvement in Gland Function and Symptoms in Patients with MGD and Dry Eye

TearScience announced the publication of a seminal prospective, multicenter clinical trial showing that a single LipiFlow treatment can deliver sustained mean improvement in meibomian gland function a…

Read the full story

Wednesday, August 10, 2016 | Dry Eye, Medical Studies

Patients With Dry Eye and Normal Visual Acuity Read More Slowly

People with dry eye read more slowly, even if they have normal visual acuity, according to a new report. Reading speed may become a tool to directly measure the functional impairment that dry eye…

Read the full story

Tuesday, August 09, 2016 | Dry Eye, Medical Studies

Medscape Survey: Many Clinicians Take Wait-and-See Attitude to New Dry Eye Drug

Indications from a Medscape survey are that clinicians will investigate lifitegrast ophthalmic solution (Xiidra, Shire) for treatment of dry eye disease (DED) now that it has been approved, but most w…

Read the full story

Thursday, July 28, 2016 | Clinical Trials, Dry Eye, Parion Sciences

Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease

Parion Sciences announced it has initiated a phase 2 clinical trial of P-321 ophthalmic dolution in patients with dry eye disease. P-321 is an inhibitor of the epithelial sodium channels (ENaC) on the…

Read the full story

Tuesday, July 26, 2016 | Dry Eye, Shire

Shire Prices Xiidra at $5K per year - Right on Par with Restasis

Dublin-based Shire has decided to roll out its new product - green-lighted by the FDA earlier this month - at about $5,000 per year, according to Evercore ISI analyst Umer Raffat. A 30-day supply will…

Read the full story

Monday, July 18, 2016 | Dry Eye, Allergan

Allergan Files De Novo Application to FDA for Approval of Oculeve Intranasal Tear Neurostimulator

Allergan announced that it has filed with the FDA the de novo application for the Oculeve Intranasal Tear Neurostimulator device. The handheld stimulator is being investigated for temporarily increasi…

Read the full story

Thursday, July 14, 2016 | Dry Eye, TearLab Corp.

TearLab Comments on Shire FDA Approval of Xiidra (Lifitegrast)

TearLab released a statement recognizing Shire on its recent FDA approval of Xiidra (lifitegrast ophthalmic solution) 5% for the treatment of signs and symptoms of dry eye disease (DED). “We …

Read the full story

Tuesday, July 12, 2016 | Dry Eye, Shire

Shire Secures Access to 16 Million-Strong US Dry Eye Disease Market With New Drug Approval

Approximately 16 million US adults diagnosed with dry eye disease will now have access to the first drug specifically indicated for this condition, following FDA approval of Shire’s lifitegrast …

Read the full story
Load More